Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilenya Off And Running, But Keeping Pace Long-Range Is Key

Executive Summary

Novartis AG's Gilenya (fingolimod) – the first oral treatment for multiple sclerosis – is off to a modestly strong start. The drug’s sales performance since its U.S. launch in October has been respectable, if not remarkable, driven by both market expansion and patient switches.

You may also be interested in...



Biogen Idec To Pursue Disability Label Claim For BG-12 Despite Missed Endpoint

Relapse reduction in multiple sclerosis was robust, though lower than in the first Phase III trial, but the drug missed the statistical mark on disability progression.

Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono

Merck Serono and Ono exchange rights to clinical programs in MS and cancer, with little cash changing hands

Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono

Merck Serono and Ono exchange rights to clinical programs in MS and cancer, with little cash changing hands

Related Content

Topics

UsernamePublicRestriction

Register

PS053671

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel